Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
31 hedge funds and large institutions have $18.7M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
173% more capital invested
Capital invested by funds: $6.87M → $18.7M (+$11.9M)
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
35% more funds holding
Funds holding: 23 → 31 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.18M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.56M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.95M |
| 4 |
PA
Perceptive Advisors
New York
|
+$2.39M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.64M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$258K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$32K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$24K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
-$3K |
FRTX Hedge Fund Activity: Q4 2017 in Review
31 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2017, worth a combined $18.7M — up 173% from $6.87M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new FRTX positions and 6 closed out — a net gain of 8 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.18M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.64M sold.
- 31 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2017, up from 23 in Q3 2017.
- Funds reported $18.7M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2017, up 173% quarter-over-quarter.
- 14 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2017 and 6 closed out, a net change of +8 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2017 was Armistice Capital, an estimated $4.18M added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $1.64M sold.
Based on aggregated 13F filings for Q4 2017.